TY - JOUR
T1 - Techniques for physicochemical characterization of nanomaterials
AU - Lin, Ping Chang
AU - Lin, Stephen
AU - Wang, Paul C.
AU - Sridhar, Rajagopalan
N1 - Funding Information:
This work was supported in part by NIH/National Institute of Minority Health Disparities G12 MD007597 , and US Army Medical Research and Material Command W81XWH-10-1-0767 grants.
PY - 2014/7
Y1 - 2014/7
N2 - Advances in nanotechnology have opened up a new era of diagnosis, prevention and treatment of diseases and traumatic injuries. Nanomaterials, including those with potential for clinical applications, possess novel physicochemical properties that have an impact on their physiological interactions, from the molecular level to the systemic level. There is a lack of standardized methodologies or regulatory protocols for detection or characterization of nanomaterials. This review summarizes the techniques that are commonly used to study the size, shape, surface properties, composition, purity and stability of nanomaterials, along with their advantages and disadvantages. At present there are no FDA guidelines that have been developed specifically for nanomaterial based formulations for diagnostic or therapeutic use. There is an urgent need for standardized protocols and procedures for the characterization of nanoparticles, especially those that are intended for use as theranostics.
AB - Advances in nanotechnology have opened up a new era of diagnosis, prevention and treatment of diseases and traumatic injuries. Nanomaterials, including those with potential for clinical applications, possess novel physicochemical properties that have an impact on their physiological interactions, from the molecular level to the systemic level. There is a lack of standardized methodologies or regulatory protocols for detection or characterization of nanomaterials. This review summarizes the techniques that are commonly used to study the size, shape, surface properties, composition, purity and stability of nanomaterials, along with their advantages and disadvantages. At present there are no FDA guidelines that have been developed specifically for nanomaterial based formulations for diagnostic or therapeutic use. There is an urgent need for standardized protocols and procedures for the characterization of nanoparticles, especially those that are intended for use as theranostics.
KW - Image contrast agents
KW - Molecular imaging
KW - Nanomedicine
KW - Nanoparticle
KW - Physicochemical properties
UR - http://www.scopus.com/inward/record.url?scp=84902002680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902002680&partnerID=8YFLogxK
U2 - 10.1016/j.biotechadv.2013.11.006
DO - 10.1016/j.biotechadv.2013.11.006
M3 - Review article
C2 - 24252561
AN - SCOPUS:84902002680
SN - 0734-9750
VL - 32
SP - 711
EP - 726
JO - Biotechnology Advances
JF - Biotechnology Advances
IS - 4
ER -